Shares in Neuren Pharmaceuticals advanced in morning trade after Macquarie initiated coverage of the biopharmaceutical company with an 'outperform' rating.

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis ...

IT's an incontrovertible fact that, as the political scientist John Mearsheimer, co-author of the landmark book, 'The Israel ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Capturing and using natural and waste heat: how heat pump technologies are transforming ‘free energy’ into security, savings ...

Prof. Musallam’s recognition by EHA affirms his role as a transformative figure in hematology and underscores the UAE’s growing influence in global medical research. His work continues to inspire a ...

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is ...